Come up with a name for your new list and we'll add to it:
AesRx raised a round of funding on December 10, 2013. Investors include
Fletcher Spaght Ventures.
Aesrx is a biopharmaceutical company developing drugs to target sickle cell disease and inflammatory diseases of the lower intestine, including distal ulcerative colitis, pouchitis and radiation induc…